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quality-of-life instruments has been widely reported across patient
and community-based samples. This study compares index scores
generated from contemporaneous EQ-5D (3-level version) and SF-6D
(SF-36 version) responses using scoring algorithms derived from
independently-conducted Australian population-representative dis-
crete choice experiments (DCEs), providing the ﬁrst comparative
analysis of health state valuations using the same method of valu-
ation across the full value sets. Methods: EQ-5D and SF-6D responses
from seven patient data sets were transformed into health state
valuations using published DCE-derived scoring algorithms. The
empirical comparative evaluation consisted of graphical illustration
of the location and spread of index scores, reporting of basic
descriptive statistics, exploration of between-measure differences in
mean index scores, and analysis of agreement. Results: Compared
with previously published ﬁndings regarding the comparability of
“conventional” EQ-5D and SF-6D index scores, health state valuationsee front matter Copyright & 2014, International S
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e, Burnaby, BC, Canada V5A 1S6.from the DCE-derived scoring procedures showed that agreement
between scores remained “fair” (intraclass correlation coefﬁcient
values across the seven data sets ranged from 0.375 to 0.615). Mean
SF-6D scores were signiﬁcantly lower than the respective mean EQ-5D
score across all patient groups (mean difference for the whole sample
¼ 0.253). Conclusions: The magnitude of disagreement previously
reported between EQ-5D and SF-6D index scores is not ameliorated
through the application of DCE-derived value sets; sizeable discrep-
ancies remain. These ﬁndings suggest that differences between EQ-5D
and SF-6D index scores persist because of their respective descriptive
systems. Further research is required to explore the implications of
variations in the descriptive systems of preference-based
instruments.
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Preference-based measurement of health-related quality of life
(HRQOL) has become an important area of research over recent
years, due largely to the increasing role of cost-utility analysis
and the quality-adjusted life-year (QALY) metric within reim-
bursement mechanisms across publicly funded health care sys-
tems [1–6]. Although preferences can be elicited as a means to
directly reﬂect an individual’s own valuation of his or her health
state—using techniques such as standard gamble (SG) and time
trade-off (TTO)—the current economic evaluation framework
that is practiced in many jurisdictions uses “off-the-shelf” ques-
tionnaires to capture health state valuations based on publicpreferences. While there are advocates for the use of individual
(e.g., patient) preferences, the justiﬁcation for using public pref-
erences is based on theoretical, normative, and pragmatic argu-
ments for incorporating general population values into health
care decision making [7–10].
Preference-based HRQOL measures are made up of two
components—a descriptive system and a valuation system—
and there are considerable variations within these components
across different questionnaires. The descriptive system deﬁnes
respondents’ HRQOL as one of a ﬁnite number of health states;
the dimensions and associated response options that permit
respondents to describe their current health state are ﬁxed. The
valuation component is a procedure for scoring each health stateociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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a scoring algorithm, is typically based on community-derived
preferences and provides a single index score. Irrespective of the
measure used to generate the index score, the value is inter-
preted on a scale on which one indicates full health and zero
represents a health state considered equivalent to being dead.
The purpose of the single index score is to represent the relative
value that society places on living in different health states.
Negative index scores can be generated, which represent health
states considered to be worse than death.
One of the major advantages of using standardized outcome
measures, in any area of health research, is that they provide a
common yardstick for interpreting results across studies. Cur-
rently, a number of different preference-based HRQOL measures
are used to estimate patient beneﬁt within economic evaluations,
such as 15D [11], Assessment of Quality of Life (AQoL-4D, AQoL-
6D, and the AQoL-8D) [12,13], EQ-5D (three-level and ﬁve-level
versions) [14,15], Health Utilities Index (Mark 2 and Mark 3) [16],
Quality of Well Being Self-Administered scale [17], and SF-6D (SF-
36 and SF-12 versions) [18,19]. There has also been a substantial
growth in the number of condition-speciﬁc preference-based
measures [20–22]. The availability of multiple instruments that
purport to measure the same underlying construct raises a
concern about the cross-study comparability of cost-
effectiveness evidence if different measures have been used to
generate QALYs [23–26].
Comparative evaluations of preference-based HRQOL meas-
ures have addressed many different combinations of instru-
ments; moderate agreement, at best, has been reported
between instruments, across numerous patient and
community-based samples [27–33]. The EQ-5D and SF-6D are
the two most frequently compared measures due to having
scoring algorithms derived from nationally representative,
community-based samples from the same region—the United
Kingdom [25]. Using these UK-derived scoring procedures, the
EQ-5D has a considerably larger scoring range (0.594 to 1.000)
than the SF-6D (0.301 to 1.000 for the SF-6D [SF-36]; 0.345 to 1.000
for the SF-6D [SF-12]) (further details of the EQ-5D and SF-6D are
provided in the Methods section). As a mere reﬂection of the
range of possible scores, individuals in more severe health states
tend to report lower EQ-5D scores than SF-6D scores. This led to
concerns that the SF-6D suffers from ﬂoor effects [28]. Con-
versely, evidence of ceiling effects has been widely reported for
the EQ-5D [28,32,33]. What is unclear is whether differences in
index scores are a result of variation in the respective descriptive
systems or methods of valuation, or both. Previous attempts to
look at this suggest that differences in the valuation technique
may account for some of the differences [34,35]. Furthermore, a
comparative evaluation of multiple generic instruments using
item response theory demonstrated that a simple linear function
will transform one index score into the other for poorer health
states [36]. Authors of the item response theory study suggest
that the “which instrument is better?” question (for poorer health
states only) is not one to be answered using psychometric
criteria; rather, it is an issue concerning which utility scale
correctly represents the values that the analysis wishes to reﬂect.
What would help to better understand EQ-5D and SF-6D differ-
ences would be to compare index scores that have been valued
using the same methods.
The commonly applied UK-speciﬁc EQ-5D and SF-6D health
state valuations were generated from TTO and SG exercises,
respectively [18,37]. These conventional elicitation techniques
are grounded in utility theory but impose strong assumptions
about the form of the utility function, suggesting that the
resultant index scores reﬂect preferences for health states under
a relatively narrow set of restrictions [38,39]. Concerns have also
been raised about the cognitive difﬁculty of completing TTO andSG tasks for certain populations [40]. The use of discrete choice
experiments (DCEs) to obtain health state valuations has been
proposed, offering an alternative preference elicitation technique
that has been claimed to allow for the investigation of more
ﬂexible model speciﬁcations and simpler valuation exercises for
respondents [40–42].
The aim of this study was to assess the comparability of EQ-5D
and SF-6D index scores derived from scoring algorithms con-
structed from two recent Australian population-representative
DCEs [43,44]. In addition to reporting descriptive statistics for new
scoring algorithms across a range of patient samples, the analysis
provides the ﬁrst comparative analysis of DCE-derived health state
valuations for preference-based HRQOL instruments.Methods
A summary of the EQ-5D (three-level version) and SF-6D (SF-36
version) descriptive systems is provided in Table 1, along with
details of the valuation studies and associated scoring ranges for
the DCE-derived algorithms used in the analysis. The same
information is reported for the conventional EQ-5D (TTO) and
SF-6D (SG) algorithms to provide further context. Details of the
full descriptive systems of the two measures (dimensions and
levels), illustrating the differences in wording, are provided in
Appendix 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.03.1720.
Data Set
The comparative assessment reported in this study uses the
same data set that compared TTO-derived EQ-5D index scores
and SG-derived SF-6D index scores across seven patient groups,
reported by Brazier et al. [28] in 2004. The seven patient groups
are low back pain, chronic obstructive pulmonary disease, irrita-
ble bowel syndrome, leg ulcer, menopausal women, knee osteo-
arthritis, and a group of healthy older women (75þ years). Further
details of the patient samples are reported elsewhere [28].
DCE-Derived Index Scores
The algorithms used to value EQ-5D and SF-6D health state
descriptions were derived from two independently conducted,
Australian population-representative DCEs. Brief details of these
DCE studies and resultant algorithms are provided in Appendix 2
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2014.03.1720; extensive details are reported elsewhere [43,44].
Within the DCE valuation studies, a number of model speciﬁca-
tions were estimated, investigating, among other issues, the
inclusion of higher-order interactions, nonlinear preferences with
respect to time, and the forcing of the algorithm to reﬂect any
intended monotonicity within the instrument. To address the
relevant policy consideration regarding the comparability of index
scores generated from the DCE-derived algorithms, the primary
comparative analysis reported in the current study focuses on the
recommended model speciﬁcations for the EQ-5D and SF-6D
algorithms; namely, the “Two-Factor Interaction” algorithm for
the EQ-5D and the “Main Effects” algorithm for the SF-6D [43,44].
Statistical Analysis and Sensitivity Analysis
The empirical comparative evaluation of DCE-derived index
scores consisted of: 1) graphical illustration of the location and
spread of index scores (scatter graph and box-plot); 2) reporting
basic descriptive statistics by instrument and by patient group; 3)
exploring between-measure differences in mean index scores
(ﬂoor and ceiling variation, and paired t tests); and 4) analysis of
agreement.
Table 1 – Summary details of the descriptive systems, valuation studies, and scoring ranges for the
“recommended” DCE-derived algorithms and conventional (i.e., TTO and SG) algorithms of the EQ-5D and
SF-6D*.
Instrument Details of the descriptive systems Valuation study
participants†
Range of values
EQ-5D (3-level) The EQ-5D covers ﬁve dimensions of health
(mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression), with one
question per dimension, each with three levels of
response. In total, the EQ-5D deﬁnes 243 unique
health states.
(i) 1031 0.516 to 1.000
(ii) 2997 0.594 to 1.000
SF-6D (SF-36) The SF-6D covers six dimensions (physical
functioning, role limitations, social functioning,
pain, mental health, and vitality). Eleven items
from the SF-36 are used to generate an index
score, with between three and six levels of
response. The instrument deﬁnes 18,000 unique
health states.
(iii) 1117 0.363 to 1.000
(iv) 611 0.301 to 1.000
DCE, discrete choice experiment; SF-36, Medical Outcomes Study 36-item Short Form Health Survey; SG, standard gamble; TTO, time trade-off.
* (i) Two-Factor Interaction algorithm for the EQ-5D [44]; (ii) TTO-derived EQ-5D scores [37]; (iii) Main Effects algorithm for the SF-6D [43]; (iv)
SG-derived SF-6D scores [18]. The DCE-derived algorithms used in this analysis are those that are recommended for use by the authors of the
DCE valuation studies [43,44].
† Number of participants included in the analysis phase of the respective valuation study.
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focuses on the respective index scores only. The distribution of
EQ-5D and SF-6D responses across dimensions has been reported
previously and, obviously, these responses have not changed; it is
the scoring algorithms that reﬂect societal valuation of the health
state descriptions that have changed. Assessment of the level of
agreement between the DCE-derived EQ-5D and SF-6D index
scores was based on graphical and statistical approaches, using
Bland-Altman plots and the intraclass correlation coefﬁcient (ICC),
respectively [45–47]. The Bland-Altman plot is an informative
analytic methodology that allows for the identiﬁcation of a
relationship between measurement error and the best estimate
of the “true” value. In the context of this study, the best estimate
of the true value is the mean of the EQ-5D and SF-6D index scores
being compared. In addition, to aid interpretation, the Bland-
Altman plot includes lines representing the mean difference
(solid) and the “limits of agreement” (dashed), calculated as the
mean difference  1.96 SD of the difference. Good agreement
between the measures would show a mean difference close to
zero, with approximately 5% of scatter points lying outside the
limits of agreement. For the quantiﬁcation of absolute agreement,
a single-measure ICC based on a two-way mixed analysis of
variance model was calculated [47]. The following benchmarks
were used for interpretation: 0.00 to 0.10 ¼ virtually none, 0.11 to
0.40 ¼ slight, 0.41 to 0.60 ¼ fair, 0.61 to 0.80 ¼ moderate, and 0.81
to 1.00 ¼ substantial [48].
Ceiling effects have been widely reported for the EQ-5D index
score. In lay terms, this means that respondents often report a
level-one response (indicating no problems) for each dimension
(thereby determined to be in “full health” according to the EQ-5D)
but subsequently indicate impairment by other means, such as
their response to a different outcome measure. The implication
of this ceiling effect is that respondents in good health are
systematically “dragged up” the utility scale. To explore how this
systematic elevation of EQ-5D scores affected the comparative
evaluation of contemporaneous EQ-5D and SF-6D scores, a
sensitivity analysis was performed in which respondents with a
full health classiﬁcation on the EQ-5D were excluded from the
data set and all analyses repeated. Further sensitivity analysis
examined how robust the ﬁndings were to the choice ofalgorithms in the base-case analysis. All analyses were replicated
for EQ-5D and SF-6D index scores generated from the respective
“Main Effects” algorithms [43,44]. Analyses were performed in
IBM SPSS Statistics 19.Results
Total sample size across the seven patient groups was 2436; 2249
(92%) and 2192 (90%) observations were available for the EQ-5D
and SF-6D, respectively. Paired observations (EQ-5D and SF-6D
index scores) were provided by 2112 (87%) respondents; with the
exception of descriptive statistics, the sample of paired observa-
tions is used for all analyses.
Graphical Illustration, Descriptive Statistics, and Between-
Measure Differences
Figure 1 provides a graphical representation of the total sample
for the primary model speciﬁcation comparison. Both panels
illustrate how the range of DCE-derived SF-6D scores extends
beyond that of the SG-derived SF-6D scores, providing a more
comparable range of values to the EQ-5D questionnaire; as with
the conventional scoring algorithms, the distribution of DCE-
derived SF-6D index scores remains a closer approximation to a
Normal distribution than for the EQ-5D (see Fig. 1B). A further
observation is the degree of within-respondent variation between
paired EQ-5D and SF-6D scores (see Fig. 1A). For example, negative
EQ-5D values had corresponding SF-6D values ranging from
0.363 to 0.677, while negative SF-6D scores had corresponding
EQ-5D scores ranging from 0.516 to 0.810. Respondents indicat-
ing full health on the EQ-5D (n ¼ 214 [10%]) reported decrements
in quality of life on the SF-6D that ranged from zero (meaning full
health on both measures) to 0.760. For the subsample of EQ-5D
“full health” respondents, the mean decrement in quality of life
estimated by the SF-6D was signiﬁcantly different from zero
(mean difference; 95% conﬁdence interval; P value ¼ 0.246; 0.22–
0.27; o0.001). Few respondents reported full health on the SF-6D
(n ¼ 5), or a “ﬂoor” response on either the EQ-5D (n ¼ 1) or the SF-
6D (n ¼ 12).
Fig. 1 – (A) Scatter graph showing paired DCE-derived EQ-5D
and SF-6D index scores for the primary analysis of the total
sample (n ¼ 2112). (B) Box-plot of paired DCE-derived EQ-5D
and SF-6D index scores for the primary analysis of the total
sample (n ¼ 2112). The plot depicts the median (thick line),
interquartile range (box), values within 1.5 box-lengths from
either end of the box (whiskers), and outliers (circles). DCE,
discrete choice experiment; HRQoL, health-related quality of
life.
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the scoring algorithms comprising the primary analysis, by patient
group. DCE-derived mean and median index scores were consis-
tently higher for the EQ-5D than for the SF-6D. The EQ-5D mean
score exceeded the SF-6D mean score by at least 0.190 across each
patient sample (P o 0.001 for all analyses; see Table 2).Analysis of Agreement
“Moderate” agreement was observed in the leg ulcer group only
(ICC ¼ 0.615; Table 2). All other analyses undertaken identiﬁed
“slight” or “fair” levels of agreement. Figure 2 presents the Bland-
Altman plot for the analysis of the combined data set; the solid
“mean difference” line represents the magnitude of the difference
between mean scores (mean difference ¼ 0.253). Figure 2 alsoprovides further illustration that EQ-5D scores exceed SF-6D scores
for the majority of paired observations (1866 of 2112; 88%). The
width of the limits of agreement, which reﬂects the range of
expected variation between any pair of future paired observations,
was 0.892; the percentage of scatter points above (below) the upper
(lower) limit of agreement was 2.4% (2.6%). The spread of between-
measure differences reduces toward the ends of the “average
utility” scale on the horizontal axis. This is a consequence of the
fact that average utility has an upper and lower bound, determined
by the scoring ranges of the instruments.
Sensitivity Analyses
Table 3 reports descriptive and inferential statistics for the mean
difference between EQ-5D and SF-6D scores, and ICC values, for
the whole group and each patient sample following the exclusion
of respondents with EQ-5D scores indicating full health. DCE-
derived mean scores were consistently higher for the EQ-5D than
for the SF-6D; mean differences ranged from 0.191 to 0.331 across
patient samples (P o 0.001 for all analyses). For absolute agree-
ment, classiﬁcations of ICC values were similar to the base case
analysis, that is, the highest level of agreement was observed in
the leg ulcer group, with slight or fair agreement for all other
comparisons.
Replication of analyses using index scores generated from the
Main Effects algorithms for both the EQ-5D and the SF-6D resulted in
no discernible differences when compared with the base-case anal-
ysis (in terms of observed ﬁndings and interpretation). These results
are not reported but are available from the authors on request.Discussion
Key Findings and Contribution to Knowledge
This study provides the ﬁrst comparative evaluation of DCE-
derived index scores for the EQ-5D and SF-6D and is the ﬁrst study
to compare entire value sets that are generated using the same
valuation method. The results show that a considerable degree of
disagreement exists between the two instruments, mirroring the
widely reported ﬁnding that differences exist between the conven-
tional EQ-5D and SF-6D index scores that are based on TTO and SG
techniques, respectively [27–33]. The pattern to the differences
differs, however, in a number of important respects when com-
pared with previous TTO/SG research. The scoring range of the SF-
6D is no longer limited in comparison to the EQ-5D; both instru-
ments allow for negative health state valuations (see Table 1). At
both respondent and group levels, previous work has shown that
EQ-5D scores tend to be lower than SF-6D scores for more severe
health states but here the result is the reverse, with the SF-6D
producing lower scores consistently [25,28].
Comparison with Other Studies
The data set used in the present study has previously been used
to compare the EQ-5D (TTO) and SF-6D (SG) scoring algorithms
[28], providing an opportunity to directly compare two compara-
tive evaluation scenarios for the same two instruments: “EQ-5D
(DCE) and SF-6D (DCE)” compared with “EQ-5D (TTO) and “SF-6D
(SG).” Results are similar with regard to the quantiﬁcation of
agreement, with ICC values ranging from 0.37 to 0.62 (whole
group ICC ¼ 0.54; fair agreement) for the DCE data and from 0.28
to 0.55 (whole group ICC ¼ 0.51; fair agreement) for the TTO/SG
comparison [28]. Differences exist in relation to the direction and
magnitude of variation in mean scores. In six of seven patient
groups, conventional index scores were higher for the SF-6D
(SG) than for the EQ-5D (TTO), with a mean difference of 0.045
[28, p. 879]. Comparable results in the present study show EQ-5D
Table 2 – Mean  SD EQ-5D and SF-6D index scores, difference between scores, and quantiﬁcation of agreement, by patient group*.
Sample Outcome measure n Mean  SD Median Minimum Maximum Difference in means (95% CI; P value) ICC of indices†
Whole group‡ EQ-5D 2249 0.606  0.31 0.689 0.516 1.000 0.253 (0.24–0.26; o0.001) 0.539
SF-6D 2192 0.350  0.31 0.349 0.363 1.000
LBP EQ-5D 265 0.666  0.26 0.697 0.191 1.000 0.242 (0.22–0.27; o0.001) 0.476
SF-6D 263 0.422  0.26 0.431 0.176 1.000
COPD EQ-5D 234 0.516  0.29 0.576 0.403 1.000 0.295 (0.26–0.33; o0.001) 0.375
SF-6D 230 0.226  0.26 0.217 0.363 0.931
IBS EQ-5D 306 0.695  0.26 0.776 0.081 1.000 0.261 (0.24–0.29; o0.001) 0.477
SF-6D 296 0.430  0.28 0.416 0.161 0.970
Leg ulcer EQ-5D 431 0.573  0.31 0.580 0.299 1.000 0.190 (0.17–0.21; o0.001) 0.615
SF-6D 430 0.385  0.30 0.394 0.363 1.000
Knee OA EQ-5D 411 0.439  0.33 0.576 0.299 1.000 0.334 (0.31–0.36; o0.001) 0.380
SF-6D 404 0.103  0.24 0.079 0.363 0.875
75þ y EQ-5D 320 0.649  0.29 0.697 0.516 1.000 0.234 (0.21–0.26; o0.001) 0.509
SF-6D 291 0.411  0.29 0.428 0.363 1.000
MP EQ-5D 282 0.769  0.25 0.879 0.191 1.000 0.228 (0.21–0.25; o0.001) 0.506
SF-6D 278 0.541  0.26 0.558 0.192 1.000
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; DCE, discrete choice experiment; IBS, irritable bowel syndrome; ICC, intraclass correlation coefﬁcient; LBP, low back pain;
MP, menopausal women; OA, osteoarthritis; SG, standard gamble; TTO, time trade-off.
* DCE-derived index scores relate to the respective recommended algorithms [43,44]. Descriptive statistics are derived from all observed data for the respective instruments. “Difference in
means” equals the EQ-5D score minus the SF-6D score for the sample of paired observations (for example, n ¼ 2112 for the whole group).
† Two-way ICC mixed model based on absolute agreement. When systematic differences between outcome measures (or “raters”) are considered relevant, variability in the measures
contributes to the denominator of ICC estimates and measures of absolute agreement are produced [47].
‡ In the 2004 study by Brazier et al. [28], the number of reported TTO-derived EQ-5D scores and SG-derived SF-6D index scores were 2298 and 2192, respectively. During the course of our
reanalysis, we identiﬁed 49 anomalies in the EQ-5D response data, where it was not possible to derive an index score.
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Fig. 2 – Bland-Altman plot showing the mean difference
between paired DCE-derived EQ-5D and SF-6D scores (solid
line) and associated 95% limits of agreement (dashed lines)
for the primary analysis of the total sample (n ¼ 2112). The
markers represent the difference between scores and the
average of the scores for each paired observation. DCE,
discrete choice experiment.
Table 3 – Sensitivity analysis based on the exclu-
sion of respondents with EQ-5D scores indicating
full health*.
Sample Difference in means
(95% CI; P value)
ICC of
indices
Whole group (n ¼ 1912)† 0.254 (0.24–0.26; o0.001) 0.489
LBP (n ¼ 237) 0.242 (0.21–0.27; o0.001) 0.420
COPD (n ¼ 194) 0.294 (0.26–0.33; o0.001) 0.342
IBS (n ¼ 264) 0.259 (0.23–0.28; o0.001) 0.453
Leg ulcer (n ¼ 394) 0.191 (0.17–0.21; o0.001) 0.561
Knee OA (n ¼ 378) 0.331 (0.31–0.36; o0.001) 0.366
75þ y (n ¼ 240) 0.237 (0.21–0.27; o0.001) 0.433
MP (n ¼ 205) 0.220 (0.19–0.25; o0.001) 0.483
CI, conﬁdence interval; COPD, chronic obstructive pulmonary
disease; IBS, irritable bowel syndrome; ICC, intraclass correlation
coefﬁcient; LBP, low back pain; MP, menopausal women; OA,
osteoarthritis.
* “Difference in means” equals the EQ-5D score minus the SF-
6D score.
† This subsample of respondents is derived from the total sample
of paired observations (n ¼ 2112) minus paired observations
where the EQ-5D score ¼ full health. EQ-5D “full health” was
reported by 214 individuals; however, only 200 of these 214 EQ-
5D responses had a paired SF-6D response.
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difference of 0.253 (see Table 2). There are a number of possible
explanations of these differences. One is that the SG technique,
particularly the variant used in the valuation of the SF-6D (one
that used chained values), may result in systematically higher
values compared with TTO values due to risk aversion [38]. This
would account for higher SF-6D (SG) scores at the lower end of
the utility scale but does not explain the relationship at the upper
end of the scale, where EQ-5D (TTO) scores are higher. The
inconsistent nature of the direction of the differences between
EQ-5D (TTO) and SF-6D (SG) index scores has been illustrated in a
systematic review [25].
A plausible explanation for the 2004 observation that EQ-5D
(TTO) scores exceeded SF-6D (SG) scores at the upper end of the
utility scale is the EQ-5D ceiling effect. In other words, the EQ-5D
ceiling effect systematically increases health state valuations for
respondents in good health and, by deﬁnition, this will cause
divergence between paired EQ-5D and SF-6D index scores. This
potential explanation was explored in a simple sensitivity anal-
ysis in the current study. If the EQ-5D ceiling effect is an
important explanatory factor for between-measure discrepan-
cies, one would expect mean differences and ICC statistics to
indicate greater similarity between the measures after excluding
respondents in “full health” (according to the EQ-5D). Results
showed negligible changes in mean differences and absolute
agreement across the seven patient groups, which suggests that
the ceiling effect commonly observed within EQ-5D data sets
does not explain the lack of agreement between EQ-5D and SF-6D
scores. It is worthwhile to note that an index score ceiling value
is, by deﬁnition, a consequence of accrued top-level responses for
each dimension. Ceiling effect concerns for the EQ-5D may be
alleviated by the recently developed ﬁve-level instrument [15].
Our ﬁndings support the observations of Cherepanov et al.’s
[49] examination of the underlying factor structures of HRQOL
instruments. Using data for ﬁve preference-based HRQOL meas-
ures (including the SF-6D and the EQ-5D), collected as part of the
US National Health Measurement Study, Cherepanov et al. dem-
onstrated that although the instruments seem to be sharing
similar underlying dimensions of health, the descriptive systems
differentially capture different ranges of these dimensions.Accordingly, if outcome measures are capturing different aspects
of HRQOL in their descriptive systems, it is unsurprising (and,
indeed, it should be expected) that variation in index scores is
observed. This phenomenon has also been discussed byWhitehurst
and Bryan in their comparative evaluation of EQ-5D and SF-6D
responses in a sample of individuals with nonspeciﬁc neck pain,
[T]he descriptive classiﬁcation systems differ to such an
extent that contemporaneous EQ-5D and SF-6D valuations
attached to health states should not be expected to provide
similar estimates, irrespective of the preference elicitation
technique used in the respective valuation studies. [33]
Our results corroborate the conclusions of these two studies,
demonstrating that variation in descriptive systems is a major
contributory factor to variation in index scores.
Strengths and Limitations
A signiﬁcant strength of this analysis comes from the use of a
common valuation method, using two DCE studies that are
almost identical. They used the same sampling frame and
sampling method, used very similar introductory wording and
asked the choice questions in the same way, analyzed the data
using the same econometric approach, and used the same techni-
que to convert the regression analysis into something of use for
cost-utility analysis. These two DCE studies provide the most
similar pair of valuation exercises (to date) that have been used
to explore the comparability of SF-6D and EQ-5D index scores.
It is important to note that the DCEs providing the scoring
algorithms from an Australian-representative population do
differ slightly in certain respects. Although the purpose of this
study is not to report the methodology of the DCEs, because this
has been reported elsewhere [43,44], there are two differences
that might have an effect on the comparability of the valuation
exercises. First, the approach to the design of the experiments
differed, with the EQ-5D DCE using a shift-generator approach
[50], while the SF-6D DCE used the SAS algorithms of Kuhfeld [51].
Second, although both DCEs offered combinations of health
states and duration, the range of durations was not the same
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 7 0 – 5 7 7576(1–16 years for the EQ-5D, 1–20 years for the SF-6D). If the
assumptions underpinning the QALY model hold—in particular,
risk neutrality with respect to time—this is irrelevant. Evidence
suggests, however, this is not a realistic assumption [52,53]. Our
view, which is not easily tested using the available data, is that
neither experimental difference (the experimental design or the
range of duration) is a plausible explanation for the large
observed differences in utility scores between the two DCE-
derived algorithms. A third potential limitation, linked to dis-
cussion as to whether the two DCEs can be deemed “almost
identical,” relates to the upper anchor. For both DCE valuation
studies, the upper anchor was deﬁned by the respective instru-
ment’s best possible health state (11111 for the EQ-5D; 111111 for
the SF-6D). This upper anchor deﬁnition could have implications
for the comparability of scores if the SF-6D state 111111 is “better”
than the EQ-5D state 11111 (or vice versa), although it should be
noted that such a limitation would be relevant for all compara-
tive evaluations of preference-based measures. It is inevitable
that methodological differences between the DCE valuation
studies will affect the observed differences between EQ-5D and
SF-6D index scores. At present, the direction and magnitude of
these effects (experimental design, duration, and upper anchor)
are unknown.
Although not a study limitation per se, it is appropriate to
interpret the correlation coefﬁcients with a degree of caution and
in conjunction with the “mean difference” ﬁndings rather than in
isolation. Correlation between outcome measures is subject to
bias by measurement error and it would be valuable to know the
degree to which an instrument agrees with itself (test-retest
reliability) to put low correlations between instruments into
perspective. The implications of measurement error are no
greater in the current study than other preference-based com-
parative evaluations.
Implications and Areas for Future Research
The magnitude and direction of the difference in mean scores
between the two instruments for all patient groups is a surprising
result. To identify the degree to which these ﬁndings affect
health care decision making, however, it is necessary to extend
the work presented here and apply the DCE-derived algorithms to
patient-level data in a clinical trial setting or cost-effectiveness
decision model. Although EQ-5D scores were consistently higher
than SF-6D scores, it remains unknown whether improvements
in utility resulting from an intervention (i.e., change scores in
utility measures over time and, more speciﬁcally, incremental
QALY estimates in a cost-utility framework) differ between the
instruments. It should be acknowledged, however, that even if
utility increments over time are similar across instruments, the
consequences of mean score discrepancies are important for life-
extending interventions, or circumstances in which disease
severity is a key consideration in prioritizing health care. Further
work to understand the practical implications of between-
measure discrepancies for health care decision making is needed
in all areas of comparative research for utility measures, not just
“new” algorithms.
Economic evaluation is, by necessity, an applied and highly
pragmatic discipline. An example of this inherent pragmatism
can be seen in the Guide to the Methods of Technology Appraisal
2013, published by the National Institute for Health and Care
Excellence (NICE) (formerly, the National Institute for Health and
Clinical Excellence) in the United Kingdom [3]. In the 2013
guideline update, NICE stated an explicit preference for the EQ-
5D for measuring and valuing health effects for technology
appraisals. NICE’s position does not infer that the EQ-5D is the
“best” measure, nor does it imply that methodological develop-
ment and comparative assessment of existing preference-basedHRQOL measures is futile. It merely reﬂects the trade-off between
analytic uncertainty and practical necessity. The continued use of
existing preference-based HRQOL measures, with their accepted
methodological shortcomings, is inevitable, and it is not our
intention to argue against this. In parallel with ongoing applied
research, further investigation is needed to understand the
between-measure discrepancies attributable to descriptive classi-
ﬁcation systems so as to inform methodological debate and guide
instrument selection for future studies—an issue that is relevant
for both generic and condition-speciﬁc preference-based measures.Conclusions
Sizeable discrepancies between the EQ-5D and SF-6D are likely to
be inevitable, irrespective of the preference elicitation techniques
adopted in the respective valuation exercises. If the mechanism
by which respondents are asked to describe their health state
differs signiﬁcantly across instruments, there is no basis for
expecting comparable index scores. Knowing that commonly
used instruments provide different individual-level values (and
group mean scores) is an important policy consideration. Beyond
the policy implication, knowing why measures differ and under-
standing the respective roles of the descriptive systems and
valuation procedures is necessary to comprehend the underlying
nature of between measure discrepancies. Further research is
required to explore the implications of variations in the descrip-
tive systems of preference-based instruments.Supplemental Materials
Supplemental material accompanying this article can be found in
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